• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Xeris Biopharma Holdings (XERS) Could Be 17% Undervalued On New Clinical Data

    Simply Wall St·10/26/2026 14:29:55
    Listen to the news

    Xeris Biopharma Holdings (XERS) has presented new clinical and scientific data on Gvoke, Recorlev and its investigational XP-8121 thyroid program to specialists at three major medical meetings this fall.

    Recent trading has been choppy for Xeris Biopharma Holdings, with the share price down 6.1% over the past day and 6.9% over the past week, yet still showing a 30 day share price return of 12.1% and a 90 day gain of 23.8% as investors weigh these data presentations. Over a longer stretch, the ticker’s year to date share price return of 38.8% and a three year total shareholder return of a little over 5x suggest that momentum has been building, even if the one year total shareholder return of 9.6% points to a cooler recent phase as the story around products like Gvoke, Recorlev and XP-8121 develops.

    Scan 21 high quality undiscovered gems that, like Xeris Biopharma Holdings, are pushing forward in specialized therapies where fresh clinical data can quickly reshape the investment story.

    Bulls see Xeris Biopharma Holdings turning clinical traction and recent share gains into support for a richer valuation. Bears point to ongoing losses and volatility. Which story fits the current price tag?

    Most Popular Narrative: 17% Undervalued

    Xeris Biopharma Holdings last closed at $10.20, compared with a widely followed fair value estimate of $12.29. This frames a materially discounted setup that hinges on how investors view XP-8121 and the commercial endocrine portfolio.

    The impending launch of XP-8121, which utilizes proprietary delivery technology to address a significant unmet need in hypothyroidism, opens the door to a high-value market segment underserved by innovation, potentially driving new revenue streams and long-term margin expansion.

    See why 9 investors see Xeris Biopharma Holdings as 17% undervalued.

    Result: Fair Value of $12.29 (UNDERVALUED)

    Still, the Xeris Biopharma Holdings narrative could crack if XP-8121 stumbles in Phase 3 or if expectations around Recorlev uptake prove too optimistic.

    Find out about the key risks to this Xeris Biopharma Holdings narrative.

    Next Steps

    Mixed views like these only matter if you test them against your own reading of the facts and move before sentiment swings again. To weigh both sides with one view, start with 3 key rewards and 1 important warning sign.

    Ready To Hunt For Your Next Idea Beyond Xeris Biopharma Holdings?

    Do not stop with Xeris Biopharma Holdings alone. Use the Simply Wall Street screener to surface fresh ideas that fit your risk comfort and return goals.